Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

BOSTON--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced it ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome for drug development, today announced a new publication in The Proceedings of the ...

Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...

Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Antiretroviral drugs help prevent HIV from replicating in the body.

On June 5, 1981, national health experts published accounts of a strange infection circulating around Los Angeles. The U.S. Centers for Disease Control and Prevention (CDC) reported on that day that, ...

Merck, known as MSD outside the United States and Canada, has announced the presentation of results from the DRIVE-AHEAD study, the second of two pivotal phase 3 clinical trials evaluating the ...

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...